CROs/Service Providers

Recipharm pours €40M into serialization

Tuesday, February 16, 2016

Recipharm, a contract development and manufacturing organization (CDMO), has taken the decision to lead the market in coding and serialization to actively help pharmaceutical companies prepare for the implementation of new regulations. 

[Read More]

Pharmaron acquires Quotient Bioresearch

Friday, February 5, 2016

Pharmaron, a fully integrated CRO offering laboratory and manufacturing services for pharmaceutical and biotech research and development, has acquired Quotient Bioresearch. Quotient, a U.K.-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.

[Read More]

BioClinica announces post-approval research service

Tuesday, February 2, 2016

BioClinica, a specialty clinical trials services and technology provider, has launched its newest service line offering. The Post-Approval Research division of its Global Clinical Research business segment was created to meet the rapidly growing and ever-evolving needs of the post-approval research industry.

[Read More]

Icon releases Flex Advantage for patient randomization

Tuesday, February 2, 2016

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has launched Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomization and clinical supply management capabilities and supports the execution of adaptive trials.

[Read More]

BioClinica acquires Clinverse

Monday, January 25, 2016

BioClinica, a specialty clinical trials services and technology provider, has acquired Clinverse. The acquisition expands Bioclinica’s offerings into the growing market of automated financial management technology solutions for global clinical trials. Clinverse is the latest investment that Bioclinica has completed to build the company into a leading provider of solutions that bring quality and efficiency to every phase of clinical trial development.  

[Read More]

Parexel to acquire Health Advances

Wednesday, January 20, 2016

Parexel International, a global biopharmaceutical services organization, has entered into a definitive agreement to acquire all outstanding equity securities of Health Advances, an independent life sciences strategy consulting firm. Health Advances combines clinical, scientific and business expertise to provide strategic advice to executives leading life sciences companies and investors.

[Read More]